Showing 1371-1380 of 5603 results for "".
Case Review: Can You Crack This IBD Case?
https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
https://reachmd.com/programs/cme/her2-breast-cancer-with-brain-metastases-rethinking-first-line-treatment-in-the-adc-era/56518/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/Which patients with HFrEF may benefit from additional evidence-based therapies beyond GDMT? Join Drs. Lam and Bauersachs in this case-based discussion.CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
https://reachmd.com/programs/cme/cdh6-in-focus-advancing-biomarker-driven-strategies-for-platinum-resistant-ovarian-cancer/36229/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerSafety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Cracking the Code of Obstruction: Unmet Needs in oHCM
https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Innovations in Precision Medicine: Leveraging Guideline-Based Immunotherapy and Targeted Treatments in Gynecologic Oncology
https://reachmd.com/programs/cme/Innovations-in-Precision-Medicine-Leveraging-Guideline-Based-Immunotherapy-and-Targeted-Treatments-in-Gynecologic-Oncology/37235/Multidisciplinary experts explore biomarker-driven strategies, immunotherapy, and personalized care in cervical and endometrial cancer management.MOA: CDH6-Targeted Antibody-Drug Conjugates
https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerPartnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making
https://reachmd.com/programs/cme/partnering-with-patients-improving-first-line-treatment-selection-in-upper-gi-cancers-through-shared-decision-making/36579/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making